The ASEAN Diagnostics Development (DxD) Initiative is pleased to accept R&D project proposals aligned with diagnostics for Dengue, Tuberculosis, Hepatitis B, and Malaria for CY 2019.

The ASEAN Diagnostics Development (DxD) Initiative is a joint program of Philippine’s ASEAN Network for Drugs, Diagnostics, Vaccines, and Traditional Medicines Innovation (ASEAN-NDI) and Singapore’s Diagnostics Development Hub (DxD Hub) which focus to co-develop diagnostic products among ASEAN Member States (AMS) that will address the unmet clinical needs in ASEAN. The initiative was approved by the ASEAN last May 2018 during its COST-74 meeting in Thailand.

The Initiative will give a priority to proposals that are strategically fit and beneficial to ASEAN. Likewise, medical value, workflow efficiency, competitive landscape, and commercial attractiveness in the development of product are important and necessary as the drugs/expected outcome should be market-ready.

We encourage interested participants to submit proposals via email to This email address is being protected from spambots. You need JavaScript enabled to view it. and attach the following documents not later than 31 May 2019:

• Completed project proposal template of ASEAN DxD Initiative
• Curriculum Vitae (CV) of team members

Chosen proposals will be co-funded by DxD Hub amounting to $50,000 USD. Visit aseandxd.com for the details of application such as proposal form and evaluation criteria.